Clinical trial NCT06265220: AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Official title: A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Lupus Nephritis - WHO Class III
Lupus Nephritis - WHO Class IV
Refractory Systemic Lupus Erythematosus
SLE
Keywords: SLE
Lupus
Lupus Nephritis
AlloNK
Lead sponsor: Artiva Biotherapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2024-02-20
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies.

This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches, or other forms of refractory systemic lupus erythematosus.

The primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus a B-cell depleting mAb (e.g., rituximab, obinutuzumab) after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V, or other forms of refractory systemic lupus erythematosus.

Patients will be assigned to receive either AB-101 alone as monotherapy or in combination with a B-cell depleting mAb (e.g., rituximab, obinutuzumab). All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and response status.

Patients may receive up to 2 cycles of treatment spaced 24 weeks apart.


Eligibility criteria: Inclusion Criteria for all subjects (Lupus Nephritis or SLE)

* Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria
* Subjects must have had an inadequate response with at least two prior lines of standard of care (SoC) treatment.

Inclusion Criteria for LN:

* Adult subjects with lupus nephritis Class III or IV (with or without the presence of Class V)
* Evidence of active disease on renal biopsy.
* All subjects are required to receive adequate concomitant antihypertensive and antiproteinuric therapy with blockade of the renin-angiotensin system

Inclusion Criteria for SLE:

* Total systemic lupus erythematosus disease activity index (SLEDAI-2K score) ≥ 8, and clinical SLEDAI-2K ≥ 4.
* British Isles Lupus Assessment Group 2004 (BILAG-2004) activity score of A in ≥ 1 organ, or a BILAG-2004 activity score of B in ≥ 2 organs.
* Subjects have failed at least two conventional therapies

Exclusion Criteria:

* Known past or current malignancy
* Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE
* Subjects with known active viral infections
* Severe active CNS Lupus

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events
timeFrame: From the time of consent through 104 weeks after initiation of study treatment
measure: AB-101 Clinical Activity
timeFrame: From the time of first dose through 104 weeks after initiation of study treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Artiva Clinical Trial Site
state: Alabama
city: Tucson
country: United States
facility: Artiva Clinical Trial Site
state: Arizona
city: Foster City
country: United States
facility: Artiva Clinical Trial Site
state: California
city: San Diego
country: United States
facility: Artiva Clinical Trial Site
state: California
city: Aventura
country: United States
facility: Artiva Clinical Trial Site
state: Florida
city: Plantation
country: United States
facility: Artiva Clinical Trial Site
state: Florida
city: Statesville
country: United States
facility: Artiva Clinical Trial Site
state: North Carolina
city: The Woodlands
country: United States
facility: Artiva Clinical Trial Site
state: Texas
Study officials:
affiliation: Artiva Biotherapeutics
name: Michael Saddekni, M.D., PgDip, BCMAS
role: STUDY_DIRECTOR
References: